Antenatal phenobarbital for reducing neonatal jaundice after red cell isoimmunization

dc.contributor.authorThomas, J.
dc.contributor.authorMuller, P.
dc.contributor.authorWilkinson, C.
dc.date.issued2007
dc.descriptionThis version first published online: April 18. 2007 Last assessed as up-to-date: June 24. 2009
dc.description.abstractBackground Neonates from isoimmunized pregnancies have increased morbidity from neonatal jaundice. The increased bilirubin from haemolysis often needs phototherapy, exchange transfusion or both after birth. Various trials in pregnant women who were not isoimmunized but had other risk factors for neonatal jaundice have shown a reduction in need for phototherapy and exchange transfusion by the use of antenatal phenobarbital. A recent retrospective case-controlled study showed reduction in the need for exchange transfusion for the neonates from isoimmunized pregnancies. Objectives To assess the effects of antenatal phenobarbital in red cell isoimmunized pregnancies in reducing the incidence of phototherapy and exchange transfusion for the neonate. Search strategy We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (June 2009). Selection criteria Randomised and quasi-randomised controlled trials of pregnant women established to have red cell isoimmunization in the current pregnancy during their antenatal testing and given phenobarbital alone or in combination with other drugs before birth. Data collection and analysis All three review authors independently assessed study eligibility and quality. Main results No trials met the inclusion criteria for this review. Authors' conclusions The use of antenatal phenobarbital to reduce neonatal jaundice in red cell isoimmunized pregnant women has not been evaluated in randomised controlled trials.
dc.description.statementofresponsibilityJoseph T Thomas, Peter Muller, Christopher S Wilkinson
dc.identifier.citationCochrane Database of Systematic Reviews, 2007; 2(2):CD005541-
dc.identifier.doi10.1002/14651858.CD005541.pub2
dc.identifier.issn1469-493X
dc.identifier.issn1469-493X
dc.identifier.orcidWilkinson, C. [0000-0003-1438-0422]
dc.identifier.urihttp://hdl.handle.net/2440/58882
dc.language.isoen
dc.publisherUpdate Software Ltd
dc.rightsCopyright © 2009 The Cochrane Collaboration. Published by John Wiley and Sons, Ltd..
dc.source.urihttps://doi.org/10.1002/14651858.cd005541.pub2
dc.subjectHumans
dc.subjectRh Isoimmunization
dc.subjectJaundice, Neonatal
dc.subjectPhenobarbital
dc.subjectExcitatory Amino Acid Antagonists
dc.subjectPrenatal Care
dc.subjectPregnancy
dc.subjectInfant, Newborn
dc.subjectFemale
dc.titleAntenatal phenobarbital for reducing neonatal jaundice after red cell isoimmunization
dc.typeJournal article
pubs.publication-statusPublished

Files